We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




DNA Minicircle Technique for Stem Cell Reprogramming to Be Commercialized

By LabMedica International staff writers
Posted on 29 Jun 2010
Pluripotent stem cells can be generated from adult human adipose stem cells by using nonintegrating minicircle DNA plasmids that contain the minimum amount of DNA required to reprogram the cells.

The minicircle method has several advantages over conventional virus or bacterial plasmid procedures for cell reprogramming. More...
DNA minicircles do not integrate into the cell's genome and are naturally lost as the cells divide, overcoming some the safety concerns associated with current reprogramming methods. Since minicircles contain no bacterial plasmid backbone DNA, they are able to evade silencing mechanisms that cells naturally use against foreign DNA.

The DNA minicircles are a type of vector that can be either transfected or electroporated into cells to allow for expression of the reprogramming factors. The mini-circle plasmid remains in the cytoplasm of the cell and is eventually lost from the dividing cells. This approach eliminates integration-site expression variability and mutagenesis that is a drawback to viral approaches that have been used to date.

A paper describing the use of DNA minicircles was published in the March 1, 2010, issue of the journal Nature Methods by investigators at Stanford University (Palo Alto, CA, USA). Now it has been announced that the biotechnology company STEMCELLS Technologies Inc. (Vancouver, Canada) has obtained a license from Stanford University to exploit the technology on a commercial basis and intends to market the DNA minicircles as a product called "STEMcircles”.
"The addition of nonviral, nonintegrating STEMcircle reprogramming vectors to our current product offering is an exciting new opportunity for STEMCELL Technologies as a leading provider of standardized, innovative and high quality tools for pluripotent stem cells,” said Alaine Maxwell, product manager of pluripotent stem cell biology at STEMCELL Technologies.

Related Links:
Stanford University
STEMCELLS Technologies Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
POC Immunoassay Analyzer
Procise DX
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.